As informed by Department of Pharmaceuticals, National Pharmaceutical Pricing Authority vide order S.O. 1041(E) dated 27th February, 2019, has put a cap on Trade Margin of 42 selected non-scheduled anti-cancer medicines on pilot basis under ‘Trade Margin Rationalization’ approach. Ribociclib was also included in this.
The Government of India has taken several measures to encourage domestic manufacturing of pharmaceutical drugs including its APIs / bulk drugs (including those required for cancer treatment) to boost domestic manufacturing. The major Programmatic interventions to support Pharma Industries include Production Linked Incentive (PLI) scheme for Pharmaceuticals and for the Bulk drugs, the schematic interventions are PLI scheme for Bulk Drugs and Bulk Drugs Parks scheme. The Production Linked Incentive (PLI) Scheme for Pharmaceuticals launched in FY 2020 - 21 provides financial incentive to 55 selected applicants for manufacturing of approved eligible products under three categories including anti-cancer drugs (Product Category – 3) for a period of six years. One PLI applicant is manufacturing the Abemaciclib Intermediate and Ribociclib Intermediate under the sub-category of Active Pharmaceutical Ingredients/ Key Starting materials/ Drug Intermediates.
As per the Indian Council of Medical Research-National Cancer Registry Programme data, the estimated number of incidences of breast cancer in the country for the year 2022 is 216108. As per Central Drugs Standard Control Organization (CDSCO), palbociclib has gone off patent on 10th Jan 2023.
Quality generic medicines are made available at affordable prices to all, under Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) in collaboration with the State Governments. Affordable Medicines and Reliable Implants for Treatment (AMRIT) Pharmacy stores have been set up in some hospitals/institutions, with an objective to make available Cancer drugs at a substantial discount vis-à-vis the Maximum Retail Price.
The Union Minister of State for Health and Family Welfare, Dr. Bharati Pravin Pawar stated this in a written reply in the Rajya Sabha today.
****
MV
HFW/ PQ /Update on medicine on breast cancer/28March2023/2